Enhertu Phase III results to redefine how metastatic breast cancer is classifed
Enhertu is a HER2-directed antibody drug conjugate (ADC) being jointly developed by AstraZeneca and Daiichi Sankyo.
Enhertu is a HER2-directed antibody drug conjugate (ADC) being jointly developed by AstraZeneca and Daiichi Sankyo.
According to the state government, it will also provide support to special projects such as preclinical testing, genome sequencing in the private sector, private sector BSL-3 lab-vaccine development and manufacturing and testing and certification laboratories
According to the Indian Journal of Medical Research in 2018, the estimated prevalence of pre-diabetes in India is 14%, which means that one out of six Indians is pre-diabetic
CEPI is accelerating its programme to develop broadly protective coronavirus vaccines—a core part of US $ 3.5 billion pandemic preparedness plan
By connecting a leading LongBio VC to the DeSci (decentralized science) movement, this partnership is a major milestone for the greater decentralized ecosystem
The companies plan to use the proceeds to retire debt and expand operations
This decision does not impact the ongoing AReSVi 006 phase III trial for RSV older adults.
In the interim, Deepak Khanna will lead Human Health International.
Covaxin is a whole-virion inactivated Covid-19 investigational vaccine candidate that uses the same vero cell manufacturing platform that has been used in the production of polio vaccines for decades
Phase 2a clinical proof-of-concept biomarker study for PXL065 in ALD now anticipated to start midyear
Subscribe To Our Newsletter & Stay Updated